Spain moves to decentralise medtech R&D (research and development) with new E9 million centre:
This article was originally published in Clinica
Executive Summary
Spain is to establish a new national regenerative medicine research centre in Barcelona, in line with a new national policy to decentralise healthcare R&D. Under an agreement signed between the Spanish health ministry and the Catalan regional government, the centre will be responsible for creating stem cell lines of embryonic and adult origin, as part of a national R&D programme that it will be responsible for devising in this area. The centre will be based at the biomedical research park of Barcelona (RRBB) and receive central funding totalling euro9m ($10.9m) by 2007.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.